Skip to main content
Ramon Klein Geltink on Muck Rack

Ramon Klein Geltink

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ramon Klein

Contact Ramon Klein, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy - Nature Communications

|
By Lior Goldberg, Eric Haas, Jiaqi Wu, Bryan Garcia, Bryan García, Ryan Urak, Vibhuti Vyas, Ruby Espinosa, Tamara Muñoz, Shirley Bierkatz, Khyatiben V. Pathak, Nathaniel Hansen, Patrick Pirrotte, Jyotsana Singhal, James L. Figarola, Ricardo Zerda Noriega, Zhuo Li, Dasol Wi, Erin Tanaka, Ramon Klein Geltink, Min-Hsuan Chen, Xiwei Wu, Jamie Wagner, Jinny Paul, Mary Clark, Dat Q Ngo, Ibrahim Aldoss, Stephen J. Forman, Xiuli Wang
| Nature Verified
Abstract Although most patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) receiving CD19-targeted chimeric antigen receptor (CAR) T cell therapy achieve remission, loss of CAR T cell functionality and subsequent relapse remains an unmet therapeutic need. Herein, we apply an integrative approach to study the immunometabolism of pre- and post-infusion CD19-CAR T cells of patients with relapsed/refractory B-ALL.
Open in Who Shared Issue with article?
See all 1 articles